| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Institute of Pathology,*
University of Berne, Berne,
Switzerland, and the Department of Integrative Biology and
Pharmacology,
University of Texas, Houston
Medical School, Houston, Texas
Human tumors frequently express somatostatin receptors. However, none of the receptor subtype proteins have been individually visualized in normal or neoplastic human tissues. Here, the distribution of the sst2A receptor was investigated using immunohistochemistry with the specific anti-peptide antibody R2–88 in 47 human tumors. All tumors selected for their abundance of sst2 mRNA and/or strong binding of the sst2-preferring ligand 125I-labeled Tyr3-octreotide were specifically immunostained with R2–88. Conversely, all tumors without somatostatin binding or expressing predominantly other somatostatin receptor subtype mRNAs (sst1 or sst3) were not specifically immunostained by R2–88. Specificity was shown in immunoblots, demonstrating receptor migration as a 70-kd broad band. In immunohistochemical and immunoblotting experiments, the abolition of staining after antibody blockade with antigen peptide was demonstrated. Immunostaining was identified in cryostat and in formalin-fixed, paraffin-embedded sections. Heat-induced epitope retrieval was necessary to visualize sst2A receptors in formalin-fixed sections. Moreover, because of occasional high nonspecific staining, the demonstration of complete abolition of immunostaining by treatment with antigen peptide was a prerequisite for the correct identification of sst2A-positive tumors. The sst2A receptors were clearly located at the membrane of the tumor cells. These results provide the first localization of a somatostatin receptor subtype in human tissues at the cellular level. The sst2A receptor identification and visualization in tumors with simple immunohistochemical methods in formalin-fixed, paraffin-embedded material will open new diagnostic opportunities for pathologists.
This article has been cited by other articles:
 |
|
 |
|
  Q. Liu, D. A. Dewi, W. Liu, M. S. Bee, and A. Schonbrunn Distinct Phosphorylation Sites in the SST2A Somatostatin Receptor Control Internalization, Desensitization, and Arrestin Binding Mol. Pharmacol., February 1, 2008; 73(2): 292 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bodei, G. Paganelli, and G. Mariani Receptor Radionuclide Therapy of Tumors: A Road from Basic Research to Clinical Applications J. Nucl. Med., March 1, 2006; 47(3): 375 - 377. [Full Text] [PDF]
|
|
|
|
|
|
R. Cescato, S. Schulz, B. Waser, V. Eltschinger, J. E. Rivier, H.-J. Wester, M. Culler, M. Ginj, Q. Liu, A. Schonbrunn, et al. Internalization of sst2, sst3, and sst5 Receptors: Effects of Somatostatin Agonists and Antagonists J. Nucl. Med., March 1, 2006; 47(3): 502 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Thodou, G Kontogeorgos, D Theodossiou, and M Pateraki Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J. Clin. Pathol., March 1, 2006; 59(3): 274 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Liu, R. Cescato, D. A. Dewi, J. Rivier, J.-C. Reubi, and A. Schonbrunn Receptor Signaling and Endocytosis Are Differentially Regulated by Somatostatin Analogs Mol. Pharmacol., July 1, 2005; 68(1): 90 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ginj, J. Chen, M. A. Walter, V. Eltschinger, J. C. Reubi, and H. R. Maecke Preclinical Evaluation of New and Highly Potent Analogues of Octreotide for Predictive Imaging and Targeted Radiotherapy Clin. Cancer Res., February 1, 2005; 11(3): 1136 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Gugger, B Waser, A Kappeler, A Schonbrunn, and J C Reubi Cellular detection of sst2A receptors in human gastrointestinal tissue Gut, October 1, 2004; 53(10): 1431 - 1436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Liu, J.-C. Reubi, Y. Wang, B. J. Knoll, and A. Schonbrunn In Vivo Phosphorylation of the Somatostatin 2A Receptor in Human Tumors J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 6073 - 6079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Hofland and S. W. J. Lamberts The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance Endocr. Rev., February 1, 2003; 24(1): 28 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Vernejoul, P. Faure, N. Benali, D. Calise, G. Tiraby, L. Pradayrol, C. Susini, and L. Buscail Antitumor Effect of in Vivo Somatostatin Receptor Subtype 2 Gene Transfer in Primary and Metastatic Pancreatic Cancer Models Cancer Res., November 1, 2002; 62(21): 6124 - 6131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hejna, M. Schmidinger, and M. Raderer The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann. Onc., May 1, 2002; 13(5): 653 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Szepeshazi, A. V. Schally, G. Halmos, P. Armatis, F. Hebert, B. Sun, A. Feil, H. Kiaris, and A. Nagy Targeted Cytotoxic Somatostatin Analogue AN-238 Inhibits Somatostatin Receptor-positive Experimental Colon Cancers Independently of Their p53 Status Cancer Res., February 1, 2002; 62(3): 781 - 788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Kulaksiz, R Eissele, D Rossler, S Schulz, V Hollt, Y Cetin, and R Arnold Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies Gut, January 1, 2002; 50(1): 52 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Klisovic, M. S. O'Dorisio, S. E. Katz, J. W. Sall, D. Balster, T. M. O'Dorisio, E. Craig, and M. Lubow Somatostatin Receptor Gene Expression in Human Ocular Tissues: RT-PCR and Immunohistochemical Study Invest. Ophthalmol. Vis. Sci., September 1, 2001; 42(10): 2193 - 2201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Szepeshazi, A. V. Schally, G. Halmos, B. Sun, F. Hebert, B. Csernus, and A. Nagy Targeting of Cytotoxic Somatostatin Analog AN-238 to Somatostatin Receptor Subtypes 5 and/or 3 in Experimental Pancreatic Cancers Clin. Cancer Res., September 1, 2001; 7(9): 2854 - 2861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Reubi, B. Waser, Q. Liu, J. A. Laissue, and A. Schonbrunn Subcellular Distribution of Somatostatin sst2A Receptors in Human Tumors of the Nervous and Neuroendocrine Systems: Membranous Versus Intracellular Location J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3882 - 3891. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Benali, P. Cordelier, D. Calise, P. Pagès, P. Rochaix, A. Nagy, J.-P. Estève, P. M. Pour, A. V. Schally, N. Vaysse, et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238 PNAS, July 12, 2000; (2000) 130196697. [Abstract] [Full Text]
|
|
|
|
|
|
S. Schulz, S. U. Pauli, S. Schulz, M. Händel, K. Dietzmann, R. Firsching, and V. Höllt Immunohistochemical Determination of Five Somatostatin Receptors in Meningioma Reveals Frequent Overexpression of Somatostatin Receptor Subtype sst2A Clin. Cancer Res., May 1, 2000; 6(5): 1865 - 1874. [Abstract] [Full Text]
|
|
|
|
|
|
D. Ferone, M. P. van Hagen, D. J. Kwekkeboom, P. M. van Koetsveld, D. M. Mooy, E. Lichtenauer-Kaligis, A. Schönbrunn, A. Colao, S. W. J. Lamberts, and L. J. Hofland Somatostatin Receptor Subtypes in Human Thymoma and Inhibition of Cell Proliferation by Octreotide in Vitro J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1719 - 1726. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. W. Hipkin, Y. Wang, and A. Schonbrunn Protein Kinase C Activation Stimulates the Phosphorylation and Internalization of the sst2A Somatostatin Receptor J. Biol. Chem., February 25, 2000; 275(8): 5591 - 5599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kiaris, A. V. Schally, A. Nagy, B. Sun, K. Szepeshazi, and G. Halmos Regression of U-87 MG Human Glioblastomas in Nude Mice after Treatment with a Cytotoxic Somatostatin Analog AN-238 Clin. Cancer Res., February 1, 2000; 6(2): 709 - 717. [Abstract] [Full Text]
|
|
|
|
|
|
N. Kimura, M. Pilichowska, F. Date, I. Kimura, and M. Schindler Immunohistochemical Expression of Somatostatin Type 2A Receptor in Neuroendocrine Tumors Clin. Cancer Res., November 1, 1999; 5(11): 3483 - 3487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Reubi, J. A. Laissue, B. Waser, D. L. Steffen, R. W. Hipkin, and A. Schonbrunn Immunohistochemical Detection of Somatostatin sst2a Receptors in the Lymphatic, Smooth Muscular, and Peripheral Nervous Systems of the Human Gastrointestinal Tract: Facts and Artifacts J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2942 - 2950. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. W. Mitra, E. Mezey, B. Hunyady, L. Chamberlain, E. Hayes, F. Foor, Y. Wang, A. Schonbrunn, and J. M. Schaeffer Colocalization of Somatostatin Receptor sst5 and Insulin in Rat Pancreatic {beta}-Cells Endocrinology, August 1, 1999; 140(8): 3790 - 3796. [Abstract] [Full Text]
|
|
|
|
|
|
N. Benali, P. Cordelier, D. Calise, P. Pages, P. Rochaix, A. Nagy, J.-P. Esteve, P. M. Pour, A. V. Schally, N. Vaysse, et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238 PNAS, August 1, 2000; 97(16): 9180 - 9185. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
